Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1148-1152

  Killgore, Karla M ^a   March, Kristi L ^b   Guglielmo, B Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ciprofloxacin; Escherichia coli; Resistance; Risk factors; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFALEXIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG CHOICE; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY TRACT INFECTIONS;

EID: 3042643373     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D622     Document Type: Review

References (16)

1. Urinary tract infections. Centers for Disease Control and Prevention. Division of Bacterial and Mycotic Diseases disease information. www.cdc.gov/ncidod/dbmd/diseaseinfo/urinarytractinfections_t.htm (accessed 2003 Oct 27).
2. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002;34:1061-6.
3. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother 2001;47:781-7.
4. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995;153:117-20.
5. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-8.
6. Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JP, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999;43: 2736-41.
7. Lautenbach E, Fishman NO, Bilker WB, Castiglioni A, Metlay JP, Edelstein PH, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469-77.
8. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58.
9. Peña C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-4.
10. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.
11. Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004;171:734-9.
12. Cox CE, Marbury TC, Pittman WG, Brown GL, Auerbach SM, Fox BC, et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 2002;24:223-36.
13. Fish DN, Sahai JV. Urinary tract infections. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ. Applied therapeutics: the clinical use of drugs. 7th ed. Philadelphia: Lippincott, Williams, & Wilkins, 2000:62-13.
14. Karlowsky J, Thornsberry C, Jones M, Sahm D. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003;36:183-7.
15. National Committee on Clinical Laboratory Standards 2004 M100-S14; 24, Number 1. Performance standards for antimicrobial susceptibility testing. Wayne, PA: NCCLS.
16. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055-61.